Immunotherapy after surgery may keep early lung cancer at bay
NCT ID NCT07120282
First seen Mar 11, 2026 · Last updated May 05, 2026 · Updated 7 times
Summary
This study tests whether the immunotherapy drug tislelizumab, given after surgery, can help prevent early-stage lung cancer from coming back in people with high-risk features. About 108 adults with stage I non-small cell lung cancer that is 2-4 cm and has certain high-risk signs will receive either tislelizumab or a placebo. The main goal is to see if the drug improves the number of patients who remain cancer-free two years after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences Cancer Hospital
RECRUITINGBeijing, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.